BrightSpring has strong structural positioning in home-based healthcare, but the trade setup has deteriorated sharply. At spot $66.25, R/R is just 0.35:1 ($3.75 upside to TP1 vs $10.75 downside to stop). Q4 2025 earnings missed (EPS $0.33 vs $0.34 est), RSI sits at 73.6 overbought, and Fwd PE 37.6x with beta 1.87 means expensive and volatile. The EMA stack remains the sole strong axis. Needs a meaningful pullback to re-enter.
BrightSpring Health Services is one of the largest diversified home and community-based health services companies in the United States. The company operates through two segments: Pharmacy Solutions (specialty and infusion pharmacy, pharmacy benefit management) and Provider Services (home health, hospice, rehabilitation, behavioral health).
BrightSpring serves over 400,000 patients daily across all 50 states, serving complex patient populations that require coordinated, multi-disciplinary care. The company benefits from the structural shift away from expensive institutional care toward more cost-effective home and community-based delivery models — a trend driven by aging demographics and payer cost pressures.
| Metric | Value | Signal |
|---|---|---|
| Revenue (FY2025) | $12.91B | +28.2% YoY |
| Revenue (TTM) | $13.65B | Strong growth |
| Adj. EBITDA (FY2025) | $618M | +34.2% YoY |
| Adj. EBITDA (2026 Guide) | $795M–$825M | +29-34% YoY |
| Gross Margin (TTM) | 16.6% | Below healthcare avg |
| Operating Margin (TTM) | 3.65% | Thin |
| Net Margin (TTM) | 1.69% | Modest |
| EPS (Q4 2025) | $0.33 | Missed $0.34 est (-1.5%) |
| EPS (Q1 2026) | $0.39 | Beat +34% vs $0.29 est |
| Fwd P/E | 37.6x | Expensive |
| RSI (14) | 73.6 |
| EMA 20 | $60.99 |
| EMA 50 | $55.83 |
| EMA 200 | $41.80 |
| MACD | 2.738 |
| Signal | 2.529 |
| ATR (14) | $2.03 |
EMA stack remains perfect: EMA20 ($60.99) > EMA50 ($55.83) > EMA200 ($41.80). RSI 73.6 is above the 70 overbought threshold, and the stock is 8.6% extended above EMA20. MACD above signal (2.74 vs 2.53) confirms upward momentum. With beta 1.87, any pullback will be amplified. The trend structure is the strongest axis, but overbought RSI warns of potential near-term exhaustion.
R/R annihilated at spot (0.35:1). RSI at 73.6 overbought, Fwd PE 37.6x expensive, beta 1.87. Mandatory convertible TEUs (8M units) will dilute ~13-16% by Feb 2027. KKR selling ~35M shares via secondaries in 2026. Q4 2025 earnings missed estimates (EPS $0.33 vs $0.34 est).
BrightSpring's structural thesis (home-based healthcare shift) remains intact, but the trade setup has deteriorated. Q4 2025 earnings missed ($0.33 vs $0.34 est). At current spot, the trade offers only $3.75 to TP1 ($70) vs $10.75 risk to stop ($55.50) — a 0.35:1 R/R that is not actionable. Wait for a pullback to $60-62 or higher targets to re-enter.
This analysis is provided for informational and educational purposes only. It does not constitute financial advice, investment recommendation, or solicitation to buy or sell any security.
Past performance is not indicative of future results. All investments involve risk, including the possible loss of principal. Always conduct your own research and consult a licensed financial advisor before making investment decisions.
Data sourced from DailyTickers Gateway, Yahoo Finance, SEC EDGAR, and public market data. Accuracy is not guaranteed.